Skip to main content
. 2019 Mar 19;28(3):267–277. doi: 10.1097/MNH.0000000000000491

FIGURE 2.

FIGURE 2

Reduction in kidney events in chronic kidney disease (CKD) patients with metabolic acidosis (serum HCO3 <22 mEq/l) treated with NaHCO3 supplementation versus control. Summary of the reduction in kidney event rate (panel a) and relative risk reduction for kidney events (panel b) in CKD patients with metabolic acidosis (HCO3 <22 mEq/l) treated with NaHCO3 supplementation (active) versus control patients. Data were extracted from the respective studies listed on the x-axis and cited in the Reference section [15,16▪▪,17,18▪▪]. Kidney event rate (panel a) was significantly different for active versus control in the de Brito-Ashurst et al. [15] (P < 0.001), Garneata et al. [16▪▪] (P < 0.001), and Dubey et al. [18▪▪] (P = 0.001) studies; the data presented for Phisitkul et al. [17] were derived from the patient level data analysis described in Table 3. CKD, chronic kidney disease; HCO3, bicarbonate.